Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-10T14:10:35.998Z Has data issue: false hasContentIssue false
  • English
  • Français

Longitudinal changes in functional disability in Alzheimer's disease patients

Published online by Cambridge University Press:  13 February 2013

H. Michael Arrighi ,
Isabelle Gélinas ,
Trent P. McLaughlin ,
Jacqui Buchanan  and
Serge Gauthier
H. Michael Arrighi*
Affiliation:
Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, California, USA
Isabelle Gélinas
Affiliation:
School of Occupational and Physical Therapy, McGill University, Montreal, Quebec, Canada
Trent P. McLaughlin
Affiliation:
Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, California, USA
Jacqui Buchanan
Affiliation:
Janssen Alzheimer Immunotherapy Research & Development, LLC, South San Francisco, California, USA
Serge Gauthier
Affiliation:
McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada
*
Correspondence should be addressed to: H. Michael Arrighi, PhD, Janssen Alzheimer Immunotherapy Research & Development, LLC, 700 Gateway Blvd., South San Francisco, CA 94080, USA. Phone: +650-794-2568; Fax: +650-794-2504. Email: marrighi@janimm.com.
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: Functional impairment is a core symptom of Alzheimer's disease (AD) often measured by loss of ability to perform activities of daily living (ADL). The objective is to describe the progressive loss of specific ADL functional capabilities expressed by AD patients’ cognitive ability.

Methods: Data are from ELN-AIP-901, an observational study of cognitive progression in participants aged 50–85 with AD (n = 196), mild cognitive impairment (n = 70), or cognitively normal (n = 75). Participants were evaluated using the Mini-Mental Status Exam (MMSE) and the Disability Assessment for Dementia (DAD) every six months for ≤2 years. Hierarchical regression was used to estimate annual change in DAD and MMSE; first, by individuals’ rate of change using linear regression, then controlling for baseline diagnosis.

Results: Over a two-year period, in AD participants, a 1-point change in MMSE was associated with a 3-point change in DAD (2.79, 95% CI: 1.97–3.63); DAD items within the finance, medication, and outings subdomains were impacted earlier than other subdomains; a hierarchy of functional impairment was observed, with instrumental ADL generally impaired prior to basic ADL.

Conclusions: ADL are impacted in a progressive and hierarchical manner associated with cognitive decline, but substantial variability remains among individuals, as well as in the relative order of items affected.

Keywords

Alzheimer's disease (AD)activities of daily living (ADL)carecognitive disorderdementiadisability
Type
Research Article
Information
International Psychogeriatrics , Volume 25 , Issue 6 , June 2013 , pp. 929 - 937
Copyright
Copyright © International Psychogeriatric Association 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andersen, C. K., Wittrup-Jensen, K. U., Lulk, A., Andersen, K. and Kragh-Sørenson, P. (2004). Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health and Quality of Life Outcomes, 2, 52–58.CrossRefGoogle ScholarPubMed
de Rotrou, J.et al. (2012). DAD-6: A6-item version of the disability assessment for dementia scale which may differentiate Alzheimer's disease and mild cognitive impairment from controls. Dementia and Geriatric Cognitive Disorders, 33, 210–218.CrossRefGoogle ScholarPubMed
Feldman, H. H. and Woodward, M. (2005). The staging and assessment of moderate to severe Alzheimer's disease. Neurology, 65 (Supplement 3), S10–S17.CrossRefGoogle Scholar
Feldman, H.et al. (2001). The Disability Assessment for Dementia Scale: a 12-month study of functional ability in mild to moderate Alzheimer's disease. Alzheimer Disease and Associated Disorders, 15, 89–95.CrossRefGoogle Scholar
Feldman, H. H., van Baelen, B., Kavanagh, S. M. and Torfs, K. E. (2005). Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Disease and Associated Disorders, 19, 29–36.CrossRefGoogle ScholarPubMed
Galasko, D., Edland, S. D., Morris, J. C., Clark, C., Moh, R. and Koss, E. (1995). The Consortium to Establish a Registry for Alzheimer's Dsease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology, 45, 451–1455.CrossRefGoogle Scholar
Gauthier, S. and Ballard, C. (2009). Management of Dementia, 2nd edn. New York: Informa Healthcare, 164 pp.CrossRefGoogle Scholar
Gauthier, S., Gélinas, I. and Gauthier, L. (1997). Functional disability in Alzheimer's disease. International Psychogeriatrics, 9 (Supplement 1), 163–165.CrossRefGoogle ScholarPubMed
Gélinas, I., Gauthier, L., McIntyre, M. C. and Gauthier, S. (1999). Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. American Journal of Occupational Therapy, 53, 471–481.CrossRefGoogle ScholarPubMed
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.CrossRefGoogle ScholarPubMed
McLaughlin, T.et al. (2010). Assessment of potential measures in models of progression in Alzheimer disease. Neurology, 75, 1256–1262.CrossRefGoogle ScholarPubMed
Petersen, R. C.et al. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology, 74, 201–209.CrossRefGoogle Scholar
Salloway, S.et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73, 2061–2070.CrossRefGoogle ScholarPubMed
SAS Institute Inc. (2008). SAS Software 9.2. SAS Institute, Cary, NC.Google Scholar
Suh, G-H., Ju, Y-S., Yeon, B. K. and Shah, A. (2004). A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. International Journal of Geriatric Psychiatry, 19, 817–824.CrossRefGoogle ScholarPubMed
Supplementary material: File

Arrighi Supplementary Material

Appendix

Download Arrighi Supplementary Material(File)
File 32.7 KB